Загрузка...
How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid?
PURPOSE: The US Food and Drug Administration (FDA) communicated the potential cardiovascular risk of thiazolidinediones (rosiglitazone and pioglitazone) in 2007 and required a Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone in 2010. It also communicated in 2010 the potential risk of...
Сохранить в:
| Опубликовано в: : | Clin Ther |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5201140/ https://ncbi.nlm.nih.gov/pubmed/25976425 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clinthera.2015.04.006 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|